A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients

Dyslipidemia is common among patients on hemodialysis, but its etiology is not fully understood. Although changes in cholesterol homeostasis and fatty acid metabolism play an important role during dialysis, the interaction of these metabolic pathways has yet to be studied in sufficient detail. In th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marek Vecka, Magdalena Dušejovská, Barbora Staňková, Ivan Rychlík, Aleš Žák
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	hemodialysis non-cholesterol sterols fatty acids chronic kidney disease hypolipidemic treatment Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/cd8ec21d2ffc4785a1d47e5756f512db
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd8ec21d2ffc4785a1d47e5756f512db
record_format	dspace
spelling	oai:doaj.org-article:cd8ec21d2ffc4785a1d47e5756f512db2021-11-25T18:20:50ZA Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients10.3390/metabo111107742218-1989https://doaj.org/article/cd8ec21d2ffc4785a1d47e5756f512db2021-11-01T00:00:00Zhttps://www.mdpi.com/2218-1989/11/11/774https://doaj.org/toc/2218-1989Dyslipidemia is common among patients on hemodialysis, but its etiology is not fully understood. Although changes in cholesterol homeostasis and fatty acid metabolism play an important role during dialysis, the interaction of these metabolic pathways has yet to be studied in sufficient detail. In this study, we enrolled 26 patients on maintenance hemodialysis treatment (high-volume hemodiafiltration, HV HDF) without statin therapy (17 men/9 women) and an age/gender-matched group of 26 individuals without signs of nephropathy. The HV-HDF group exhibited more frequent signs of cardiovascular disease, disturbed saccharide metabolism, and altered lipoprotein profiles, manifesting in lower HDL-C, and raised concentrations of IDL-C and apoB-48 (all <i>p</i> < 0.01). HV-HDF patients had higher levels of campesterol (<i>p</i> < 0.01) and β-sitosterol (<i>p</i> = 0.06), both surrogate markers of cholesterol absorption and unchanged lathosterol concentrations. Fatty acid (FA) profiles were changed mostly in cholesteryl esters, with a higher content of saturated and n-3 polyunsaturated fatty acids (PUFA) in the HV-HDF group. However, n-6 PUFA in cholesteryl esters were less abundant (<i>p</i> < 0.001) in the HV-HDF group. Hemodialysis during end-stage kidney disease induces changes associated with higher absorption of cholesterol and disturbed lipoprotein metabolism. Changes in fatty acid metabolism reflect the combined effect of renal insufficiency and its comorbidities, mostly insulin resistance.Marek VeckaMagdalena DušejovskáBarbora StaňkováIvan RychlíkAleš ŽákMDPI AGarticlehemodialysisnon-cholesterol sterolsfatty acidschronic kidney diseasehypolipidemic treatmentMicrobiologyQR1-502ENMetabolites, Vol 11, Iss 774, p 774 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hemodialysis non-cholesterol sterols fatty acids chronic kidney disease hypolipidemic treatment Microbiology QR1-502
spellingShingle	hemodialysis non-cholesterol sterols fatty acids chronic kidney disease hypolipidemic treatment Microbiology QR1-502 Marek Vecka Magdalena Dušejovská Barbora Staňková Ivan Rychlík Aleš Žák A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients
description	Dyslipidemia is common among patients on hemodialysis, but its etiology is not fully understood. Although changes in cholesterol homeostasis and fatty acid metabolism play an important role during dialysis, the interaction of these metabolic pathways has yet to be studied in sufficient detail. In this study, we enrolled 26 patients on maintenance hemodialysis treatment (high-volume hemodiafiltration, HV HDF) without statin therapy (17 men/9 women) and an age/gender-matched group of 26 individuals without signs of nephropathy. The HV-HDF group exhibited more frequent signs of cardiovascular disease, disturbed saccharide metabolism, and altered lipoprotein profiles, manifesting in lower HDL-C, and raised concentrations of IDL-C and apoB-48 (all <i>p</i> < 0.01). HV-HDF patients had higher levels of campesterol (<i>p</i> < 0.01) and β-sitosterol (<i>p</i> = 0.06), both surrogate markers of cholesterol absorption and unchanged lathosterol concentrations. Fatty acid (FA) profiles were changed mostly in cholesteryl esters, with a higher content of saturated and n-3 polyunsaturated fatty acids (PUFA) in the HV-HDF group. However, n-6 PUFA in cholesteryl esters were less abundant (<i>p</i> < 0.001) in the HV-HDF group. Hemodialysis during end-stage kidney disease induces changes associated with higher absorption of cholesterol and disturbed lipoprotein metabolism. Changes in fatty acid metabolism reflect the combined effect of renal insufficiency and its comorbidities, mostly insulin resistance.
format	article
author	Marek Vecka Magdalena Dušejovská Barbora Staňková Ivan Rychlík Aleš Žák
author_facet	Marek Vecka Magdalena Dušejovská Barbora Staňková Ivan Rychlík Aleš Žák
author_sort	Marek Vecka
title	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients
title_short	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients
title_full	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients
title_fullStr	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients
title_full_unstemmed	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients
title_sort	matched case-control study of noncholesterol sterols and fatty acids in chronic hemodialysis patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/cd8ec21d2ffc4785a1d47e5756f512db
work_keys_str_mv	AT marekvecka amatchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT magdalenadusejovska amatchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT barborastankova amatchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT ivanrychlik amatchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT aleszak amatchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT marekvecka matchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT magdalenadusejovska matchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT barborastankova matchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT ivanrychlik matchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients AT aleszak matchedcasecontrolstudyofnoncholesterolsterolsandfattyacidsinchronichemodialysispatients
_version_	1718411347096502272

A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients

Ejemplares similares